PURPOSE: To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. METHODS: Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m(2)/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed. RESULTS: ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t (1/2) of 5.1 h. The apparent clearance was 33 ml/min/m(2) and was age-independent. The AUC(0-infinity) increased in proportion to the dose, and at 200 mg/m(2) the median AUC(0-infinity) was 91 mcg h/ml and the C (ave) was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min post-dose and peaked 3-5 h after the dose. The glucuronide:sulfate molar AUC(0-infinity) ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC(0-infinity) was higher in patients experiencing dose-limiting toxicity. CONCLUSIONS: Oral ABT-751 pharmacokinetics was dose-proportional and age-independent with minimal intra- and inter-patient variability in children.
PURPOSE: To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. METHODS:Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m(2)/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed. RESULTS:ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t (1/2) of 5.1 h. The apparent clearance was 33 ml/min/m(2) and was age-independent. The AUC(0-infinity) increased in proportion to the dose, and at 200 mg/m(2) the median AUC(0-infinity) was 91 mcg h/ml and the C (ave) was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min post-dose and peaked 3-5 h after the dose. The glucuronide:sulfate molar AUC(0-infinity) ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC(0-infinity) was higher in patients experiencing dose-limiting toxicity. CONCLUSIONS: Oral ABT-751 pharmacokinetics was dose-proportional and age-independent with minimal intra- and inter-patient variability in children.
Authors: Karen W L Yee; Anne Hagey; Srdan Verstovsek; Jorge Cortes; Guillermo Garcia-Manero; Susan M O'Brien; Stefan Faderl; Deborah Thomas; William Wierda; Steven Kornblau; Alessandra Ferrajoli; Maher Albitar; Evelyn McKeegan; David R Grimm; Toby Mueller; Rhonda R Holley-Shanks; Leonardo Sahelijo; Gary B Gordon; Hagop M Kantarjian; Francis J Giles Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: Christopher L Morton; Edward G Favours; Kimberly S Mercer; Claire R Boltz; Jeri Carol Crumpton; Chandra Tucker; Catherine A Billups; Peter J Houghton Journal: Invest New Drugs Date: 2007-03-24 Impact factor: 3.850
Authors: Kenneth R Hande; Anne Hagey; Jordan Berlin; Yingna Cai; Kysa Meek; Hiro Kobayashi; A Craig Lockhart; Diane Medina; Jeffrey Sosman; Gary B Gordon; Mace L Rothenberg Journal: Clin Cancer Res Date: 2006-05-01 Impact factor: 12.531
Authors: Elizabeth Fox; John M Maris; Brigitte C Widemann; Wendy Goodspeed; Anne Goodwin; Marie Kromplewski; Molly E Fouts; Diane Medina; Susan L Cohn; Andrew Krivoshik; Anne E Hagey; Peter C Adamson; Frank M Balis Journal: Clin Cancer Res Date: 2008-02-15 Impact factor: 12.531
Authors: Elizabeth Fox; John M Maris; Brigitte C Widemann; Kysa Meek; Anne Goodwin; Wendy Goodspeed; Marie Kromplewski; Molly E Fouts; Diane Medina; Steve Y Cho; Susan L Cohn; Andrew Krivoshik; Anne E Hagey; Peter C Adamson; Frank M Balis Journal: Clin Cancer Res Date: 2006-08-15 Impact factor: 13.801
Authors: Chien-Ming Li; Yan Lu; Jianjun Chen; Terrence A Costello; Ramesh Narayanan; Mara N Dalton; Linda M Snyder; Sunjoo Ahn; Wei Li; Duane D Miller; James T Dalton Journal: Pharm Res Date: 2012-07-04 Impact factor: 4.200
Authors: Federico Innocenti; Jacqueline Ramírez; Jennifer Obel; Julia Xiong; Snezana Mirkov; Yi-Lin Chiu; David A Katz; Robert A Carr; Wei Zhang; Soma Das; Araba Adjei; Ann M Moyer; Pei Xian Chen; Andrew Krivoshik; Diane Medina; Gary B Gordon; Mark J Ratain; Leonardo Sahelijo; Richard M Weinshilboum; Gini F Fleming; Anahita Bhathena Journal: Pharmacogenet Genomics Date: 2013-07 Impact factor: 2.089
Authors: Elizabeth Fox; Yael P Mosse'; Holly M Meany; James G Gurney; Geetika Khanna; Hollie A Jackson; Gary Gordon; Suzanne Shusterman; Julie R Park; Susan L Cohn; Peter C Adamson; Wendy B London; John M Maris; Frank M Balis Journal: Pediatr Blood Cancer Date: 2013-12-18 Impact factor: 3.167
Authors: Michelle A Rudek; Arvind Dasari; Daniel Laheru; Ping He; Runyan Jin; Rosalind Walker; Gretchen E Taylor; Antonio Jimeno; Ross C Donehower; Manuel Hidalgo; Wells A Messersmith; W Thomas Purcell Journal: J Clin Pharmacol Date: 2016-02-02 Impact factor: 3.126